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CROSS-REACTIVITY BETWEEN H-2K AND
H-2D PRODUCTS
I . Evidence for Extensive and Reciprocal Serological
Cross-Reactivity*
BY DONAL B. MURPHY$ AND DONALD C . SHREFFLER
(From the Department ofHuman Genetics, University of Michigan, Ann Arbor, Michigan 48104)
In the presently accepted view, the H-2 gene complex is divisible by recombina-
tion into six regions, each marked by a genetic locus controlling a distinct
function or product (Fig . 1) (1). Regions K and D determine the classical H-2
alloantigens, defined serologically and by graft rejection (loci H-2K and H-2D)
(2, 3) . The S region controls qualitative and quantitative variations in a serum
protein (Ss-Slp locus) (4) . The capacity to respond to synthetic polypeptides and
various other antigens is governed by regions I-A and I-B (loci Ir-IA and Ir-IB)
(5-7) . These latter two regions also determine a unique membrane alloantigenic
system, called la (loci Ia-1 and la-2) (8-11) . A third region for the control of la
antigens, I-C, has recently been postulated (Ia-3 locus) (1, 12) .
This current interpretation of the H-2 system assumes that only two regions
determine H-2 antigens . Early maps of the H-2 gene complex depicted multiple
regions for the control of H-2 specificities (3, 13, 14) . These maps were
constructed with the implicit assumption that no cross-reactivity occurred
between the products of separate regions, i.e ., that the genetic determinant for
reactivity with a given antiserum always mapped in a single consistent position
on the chromosome . In 1966, Shreffler et al . (15) noted certain inconsistencies in
these linear maps, and suggested that genes controlling one particular H-2
specificity might perhaps be localized at both the H-2K and H-2D ends of the
complex. This theme was later elaborated (16), and a two-region model for the
control ofH-2 determinants, based on the assumption ofH-2K-H-2D cross-reac-
tivity, was formally proposed to explain H-2 recombinant data (17, 18) . The
assumption of cross-reactivity betweenH-2K and H-2D eliminated the necessity
for additional "central" regions for control of H-2 determinants . Demant et al .
(19), Snell et al . (20), and Stimpfling (21) also proposed that genes coding for
similar determinants mightmap at opposite ends of the complex, and Snellet al .
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(22) pointed out in addition that the "private" H-2 specificities could all be
arranged into two segregant series .
Evidence favoring the two-region interpretation comes from three sources: (a)
Skin grafts survive indefinitely when exchanged between combinations in which
the multi-region model predicts incompatibility for regions other than H-2K or
H-2D (21, 23-26) . A weakness with this approach is that the multi-region maps
were constructed on the basis of serological data, not skin graft data . (b)
Antibody against an unrelated H-2 source, but reactive with H-2Kk determi-
nants, can be absorbed by H-2Dk antigen (20) . This indirect demonstration of
cross-reactivity has clearly shown H-2.1-like activity at opposite ends of the H-2
complex . Other such serological data could likewise be interpreted as implicating
H-2K-H-2D cross-reactivity (15, 16, 19, 20, 27, 28) . (c) Biochemical data reveal
only twoH-2 glycoprotein molecules, both ofwhich express multiple specificities
(29) . Since antigenic activity resides in the protein moiety, and no evidence for
subunit construction has been found, the H-2 antigens appear to be single
polypeptide products of two discrete structural genes .
The key assumption distinguishing the multi-region model from the two-region
model for control of H-2 determinants is that serological cross-reactivity occurs
between the products of the H-2K and H-2D loci . In order to test this
assumption, and provide further evidence supporting the two-region model,
antisera were prepared against determinants controlled by one region (e.g .
H-2K), and then tested in strain combinations which expressed determinants
controlled by the other region (e.g . H-2D) . Preliminary results with a few
combinations have been reported (30) . This paper presents extensive data which
confirm the existence of H-2K-H-2D cross-reactivity in many combinations, and
thus validate the assumption on which the two-region interpretation was
predicated .
Materials and Methods
Mice .
￿
All mice utilized in this study are maintained at the University of Michigan . These lines,
together with the abbreviations used in this paper, are listed in Table 1 .
Genetic Notation.
￿
This notation is based upon the recommendations of Klein et al . (32) . H-2K
and H-2D refer to genetic loci . Each locus is defined on the basis of control of a distinct function or
product and separation from other loci in the H-2complex by recombination . For brevity in the text
of this paper, the locussymbols are frequently shortened toK andD. Alleles at theH-2K and H-2D
loci are normally designated by a superscript denoting the haplotype or origin (e.g . H-2Kk, H-2Dd) .
For convenience in this paper, the allele symbols will be abbreviated (e.g . Kk,Dd).ThetermsH-2K or
K region and H-2D or D region refer to the segments of chromosome defined by intra-H-2
recombinations whichhave separated the specific marker loci (i.e . H-2K or H-2D) from adjacent loci .
The term H-2K or K end refers to the segment of chromosome situated to the left of the Ss gene,
toward the H-2K marker gene, whileH-2D or Dend refers to the segment of chromosome situated to
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TABLE I
List ofMouse Lines Used
§ See Shreffler and David (1) . Lower case letter indicates haplotype origin of each region, i .e .,
recombinant haplotype h4 has theKregion of H-2k, I-A region of H-2k, I-B region of H-2°, etc .
the right of the Ss gene, toward theH-2D marker gene . TheH-2 haplotype is normally designated by
a superscript lower case letter or combination of letter(s) and number (e .g . H-2k, H-2,+, etc.) . For
brevity andconvenience in the text ofthis paper, haplotypesymbols will also be designated simply by
the italicized superscript symbol printed on line with the text (e .g . k, h4, etc.) .
Immunizations. Animals, 15 to a group, were presensitized with a suspension of spleen and
lymph node cells injected intraperitoneally (1 donor/15 recipients, approximately 10' cells/mouse) .
After 4 wk, the mice received three additional weekly injections, and were bled 1 wk after the fourth
injection . Thereafter, animals were reimmunized every 3rd wk, andwere bled 1 wk aftereach booster .
A minimum of eight injections was given in each group . In order to maximize chances of detecting
weak cross-reactions, bleedings from each individual mouse were assayed for cross-reactive cytotoxic
activity . Those bleedings exhibiting strong or moderate activity were pooled and stored at -80°C
until further tested . A list of antisera examined forH-2K-H-2D cross-reactivity can be found in Table
II .
In F, control combinations designed to test for shared determinants, immunizations were
performed with irradiated donor cells (15,000 R) . This treatment was employed to prevent potential
complicating antibodies resultingfrom graft-vs .-host reactions . Theirradiated cells were found to be
capable of eliciting a strong humoral response .
Dye Exclusion Microcytotoxic Test . A two-stage dye exclusion microcytotoxic test was per-
formed as described by Amos et al . (33), with some modifications (34) . Cell suspensions were
prepared by teasing apartlymphnodes (axial, brachial, inguinal, mesenteric) in medium 199 fortified
with 2% fetal calf serum and 1% antibiotic-antimycotic mixture (Grand Island Biological Co ., Grand
Strain*
Abbrevi-
ation
H-2
haplo-
type$
K I-A
Haplotype
origin ofregion§
I-B 1-C S D
B10.A/SnSf B10.A a k k k d d d
B10/SnSf B10 b b b b b b b
B10.A(2R)/Sg 2R h2 k k k d d b
BlO.A(4R)/Sg 4R b4 k k b b b b
HTI/BoySf HT-1 i b b b b b d
BlO.A(5R)/Sg 511 i5 b b b b d d
B10.D2/SnSf B10.D2 d d d d d d d
B10.BR/SnSf BlO.BR k k k k k k k
C3H/HeSf C3H k k k k k k k
C3H.OL/Sf OL of d d d d k k
C3H.OH/Sf OH o2 d d d d d k
B10.A/SnSf B10.A a k k k d d d
A.AL/Sf A.AL al k k k k k d
D2.GD/Li D2 .GD g2 d d b b b b
B10.D2(R103)/Eg R103 g3 d d d d d b
AQR/Klj AQR yl q k k d d d
KBR/Sf KBR hl k k k k k b
* See Klein (31) .
$See Klein et al . (32) .DONAL B . MURPHY AND DONALD C . SHREFFLER
Island, N.Y .), separating on a Ficoll-isopaque gradient (35), and adjusting to a final cell
concentration of 5 x 10 , cells/ml . Antisera and nonimmuneserum controls were titrated by doubling
dilutions, and 2-j1 aliquots transferred to wells in microtest tissue, culture plates (Falcon Plastics,
Div . of BioQuest, Oxnard, Calif.) . All work was conducted at 4 °C except where indicated . 2 pl of the
cells were added to each well, and the plates incubated at 37°C for 15 min . A two-stage test was
performed by washing with serum-free medium before the addition of complement . Rabbit
complement, either unabsorbed or absorbed with agarose-EDTA (36), was used. After the addition of
2 g1 of complement, the reaction mixture was incubated at 37°C for 30 min . This reaction was
terminated by the addition of cold medium 199 (with fetal calf serum) in which the vital dye,
Nigrosin, had been dissolved (0.1%) . The number of live and dead cells was determined, and the
percent cell lysis calculated . Nonimmune serum controls routinely yielded a baseline of 10% or less
cell death . Antiserum titers were calculated as the dilution of serum giving 50% of the maximum
specific lysis .
Hemagglutination .
(37) .
Skin Grafting.
￿
Tail skin grafts (I cm 2 ) were placed on the right and/or left dorsal flanks of mice
anesthesized with Nembutal according to the method of Billingham and Medawar (38) . Grafts were
secured with collodion, and protected with latex-gauze bandages . I wk after grafting, this dressing
was removed, the excess collodion gently peeled off, and an ordinary Band-Aid applied forafewdays
to protect the graft from scratching. Graft survival was based on three criteria : (a) scale survival, (b)
hair growth, and (c) pigmentation . Failure to exhibit all of these characteristics constituted the basis
for classifying a graft as rejected . Chronic hair or scale loss implicated weak incompatibility .
ExperimentalDesign .
￿
Representative recombinant and parental lines utilized in this analysis are
graphically depicted in Fig. 2 . (Only the D, S, andKregions of the complex are included) . Two types
of combinations can be set up to screen for serological cross-reactivity between theK andD ends .
First, one canimmunize parental lines (e .g . 1310) with tissue from one of the recombinant strains (e .g .
4R), and then test this serum (e.g . 1310 anti-4R) with tissue from the reciprocal recombinant line (e .g .
HTI) (Fig. 2 A) . In this combination, we are testing for the ability of antibody produced against
determinants controlled by theKend ofH-2'p (anti-Kk) to react with antigen encodedby theD end of
H-2° (D°) . Note that donor, recipient, and target strains all share the same S region ; i .e ., we are
immunizing and testing across a "gap"' for S . Consequently, if one observes a reaction in this
combination, one can assert that antibody directed against some determinant controlled by a gene to
the left ofS reacts with some determinant encoded by agene to the right ofS. Apossible alternative
to this interpretation is dealt with and excluded in the next section (Controls) .
A second type of combination which can be examined involves immunizing a recombinant line
(e .g . 2R) with tissue from one parent (e.g. B10.A), and then testing this antiserum (e.g . 21?
Red cell agglutinationwasassayedby the polyvinyl pyrrolidone (PVP) method
'The term "gap" is used here in the same sense as that introduced by Demant et al . (24) .
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Antisera
TABLE II
Examined for Cross-Reactivity
Antiserum Combination Antiserum Combination no . no .
AS-1 211 anti-B10.A AS-51 OH anti-B10.D2
AS-10 511 anti-1310 AS-54 OL anti-C3H
AS-12 511 anti-B10.A AS-63 B10.D2 anti-BIO.A
AS-25 BlO.A anti-5R AS-66 411 anti-1310
AS-28 B10.A anti-2R AS-73 C3Hanti-A.AL
AS-37 B10anti-5R AS-77 B10.D2anti-OH
AS-40 C3H anti-OL AS-123 B10.D2 anti-5R
AS-43 B10.A anti-B10.D2 AS-131 (D2.GD x R103)F,anti-OH
AS-45 B10.A anti-B10.BR AS-132 (D2.GD x R103)F, anti-B10.D2
AS-49 B10anti-4R AS-134 (D2.GD x R103)F, anti-1310378
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Results
FIG. 2 .
￿
Experimental design used to test for H-2K-H-2D cross-reactivity .
anti-BIO.A) with target cells derived from thesecond parent (e .g . 1310) (Fig . 2B) . Reactivity with this
target strain could reflect (a) cross-reactivity betweenD andK end products, or (b) cross-reactivity
between determinants controlled by separate genes both in the S-D interval . One can rule out
reactivity with the S region in this combination, and artificially create a gap, by testing and
absorbing theantiserum with strain 4R . A positive reaction of the absorbed antiserum could then be
interpreted as evidence for a cross-reaction between anti-Dd antibody and K° antigen .
Atotal of eight different test combinations canbe constructed utilizing the four a/b recombinants
and their parents . Employing the same approach, eight additional combinations were examined
using the d/k recombinants, and three combinations with d/b recombinants .
Controls .
￿
Most strain combinations in this analysis were selected such that
immunization and testing took place across a gap for the S region . A positive
reaction in this casewouldbe interpreted as evidence for cross-reactivity between
theKandD products . The only tenable alternative to this interpretation would
be that donor and test strains share some histocompatibility gene missing from
the recipient . This could occur if recombination had involved a double, triple, or
unequal crossover event . For example, suppose haplotype h4 carried by strain 4R
was derived from a double or triple crossover (Fig . 3 A, B) . One could then argue
that reactivity of a B10 anti-5R (b anti-i5) serum with 411 target cells simply
reflected the sharing of some common determinant, Xd, and not cross-reactivity
between the H-2D and H-2K antigens . An unequal crossover, deleting some
segment controlling membrane alloantigens from 4R, is also possible (Fig . 3 C) .
Reactivity of a 411 anti-1310 (h4 anti-b) serum with B10.A (a) targets could in that
case reflect a direct or cross-reaction between Xb and Xk products, and not H-2D
and H-2K products .
Although any one of these rare chromosomal rearrangements is possible, data
presented in Table III argue against such occurrences. Tissue from B10 donors is
compatible with (4R x 5R)F1 recipients (Group I) . Skin grafts survive perma-
nently, and nohumoral immunity is detected in hyperimmunized animals . Thus,
H-2 Region Haplotype Origin
Strain Haplotype K S D K S D
BIO.A a d d
BIO b b b b
2R h2 0 k d b
4R h4 k b b
HTI i b b d
5R i5 b d d
A . Parent Antirecombinant
BIO Anti-4R
HTI Target
K k
C-7 Dd
I~
B. Recombinant Antiparent Dd
2R Anti-BIO.A
Absorb with 4R to Rule S-
Out Reactivity with this
-~ Segment . K b
BIO TargetDONAL B. MURPHY AND DONALD C. SHREFFLER
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A. _h4 as o double crossover.
o
￿
Kk Sd D4Z~ h4
￿
Kk S, + b Db, , Xd
b Kb Sb Db Xb
o
￿
Kk
￿
S ~ d Dd Xd ~i5
￿
Kb S J
￿
d Dd Xd
b KbJ Sb Db Xb
B. h4 as a triple crossover .
0
b
Kk Sd Xd Dd
￿
h4
Kb
Sb
Xb
Db
-r -
C. h4 as on unequal crossover (deletion) .
Kk
Sb
Xd
Db
a
￿
Kk
￿
Sd
￿
Xd
￿
Dd1 i 5
￿
Kb, Sd
￿
Xd Dd
b Kb
S
b
Xb Db
￿
--r
a
￿
Kk-X k ￿S d Dd
￿
h4
￿
~
￿
S~ b Db
Kb XbSb Db
o K k X
￿
~ i5
￿
Kb X~ k S4 Dd
b Kb Xb Sb Db
FIG. 3 .
￿
Schematic representation of h4 as a double, triple, or unequal crossover, and i5 as a
single crossover .
no detectable reaction is directed against the postulated Xb product, arguing
against any double or triple crossover . Failure of (411 x 5R)F, hybrids to
demonstrate reactivity against either parental B10 (Group I) or B10.A tissue (25)
suggests that an unequal crossover in 411, deleting a gene controlling some
membrane determinant, is also unlikely . Lack of humoral or graft responses in
the combinations included in Group I and Group 11 also argues against double,
triple or unequal crossover origins for the 211 and 511 recombinants, and further
implies that no H-gene mutation has occurred since the establishment of the 211,
411, 511, B10, and B10.A strains .
Combinations included in Group III did produce cytotoxic, nonhemagglutinat-
ing antibody capable of lysing approximately 70% of lymph node targets . This
behavior is unlike that of classical H-2 antibody (see description in K-D
Cross-Reactivity section) . Reactivity in these two combinations has been
attributed to a new H-2-linked antigen system called la.2 The weak graft
incompatibility observed with both combinations may implicate a minor
transplantation role for some genes in the segment betweenH-2K andH-2D .
It was not possible to test the d/k recombinants for compatibility with parental
hybrids in all combinations, since these haplotypes are on three different inbred
strain backgrounds (Group IV and Group V) . However, in those combinations
tested, no serologically detectable responses occurred . Unexpectedly, multiple
cases ofweak graft incompatibility were observed . The most critical combination
is (1310.1311 x B10.D2)F, hybrids grafted with B10.A skin (Group IV). Two of 10
2 David, C. S., S. E. Cullen, and D. B. Murphy . 1974 . Serologica land biochemical studies with the
la system of the mouseH-2gene complex . Further evidence foran I-Cregion .J .Immunol. In press .380
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TABLE III
Control Combinations Designed to Test for Shared Determinants
Serological
￿
Skin graft
result*
￿
result
* Reciprocal of antiserum titers.
$ 70% maximum lysis with lymph node targets .
§ Some grafts show chronic hair and scale loss.
grafts were rejected at 48 and 90 days . One of the remaining eight grafts showed
signs of chronic hair and scale loss, while the rest exhibited good viability. Since
B10.A tissue is perfectly compatible with other B10 congenic recipients (Group
I), and B10.D2 tissue is compatible with (BIO.A x C3H.OH)F, hosts (Group V),
it seems unlikely that this antigenic disparity resides in the 1110 background of
strain BIO.A. The a haplotype is a postulated recombinant between d and k (13) .
Perhaps the haplotypes from which a was derived were slightly different from
those in B10.D2 (H-2d) and B10.BR (H-2k), or perhaps mutation has since altered
one of the haplotypes. We cannot distinguish between these possibilities .
The design used here to screen for possible shared determinants in certain
combinations is similar to that employed by other investigators who tested for
Group Host Donor
Cyto-
toxic
Hemag-
glutin-
ation
No .
rejected
Days
survived
I (2R x 5R)F, B10 0 0 0/8 > 172
(2R x 5R)F, B10.A 0 0 0/8 > 171
(4R x 5R)F, B10 0 0 0/12 > 64
(4R x HTI)F, B10 0 0 0/9 ' > 171
II (B10.A x MOT, 2R 0 0 0/6 > 96
(B10.A x B10)F, 4R 0 0 0/6 > 96
(1110A x B10)F, 511 0 0 0/6 > 96
III (4R x HTI)F, B10.A 80$ 0 1/7§ 1(145)
6 > 238
(1110 x HTI)F, 5R 320$ 0 4/17§ 1(160)
3(239)
13 > 239
IV (C3H x B10.D2)F, C3H.OH 0 0 ND ND
(C3H x B10.D2)F, C3H.OL 0 0 ND ND
(B10.BR x B10.D2)F, B10.A 0 0 2/10§ 1(48)
1(90)
8 > 112
V (B10.A x C3H.OH)F, CM 0 0 0/7§ > 112
B10.BR ND ND 3/10§ 2(71)
1(113)
7>113
(B10.A x C3H.OH)F, B10.D2 0 0 0/12 > 113
(C3H.OL x A.AL)F, C3H 0 0 1/6§ 1(48)
5 > 112skin graft compatibility across H-2 barriers otherthan H-2K or H-2D (21, 23-26) .
According to the multi-region H-2 model, one would predict that humoral
immunity should be observed in the following combinations ; (2R x 5R)F,
anti-1310, (4R x 5R)F, anti-1310, (4R x HTI)F, anti-1310, and (B10.A x
C3H.OH)F, anti-B10.D2 . After prolonged immunization, no cytotoxic or hemag-
glutinating antibody was detected in any of these combinations (Table 111) .
These serological data thus complement the previous skin graft data in failing to
demonstrate immunity against those "central" H-2 regions postulated under the
older model .
In sum, these control immunizations suggest that no mutation or unusual
recombinatory event (i .e . double, triple, or unequal cross-over) transpired in the
establishment of the strains used in the experiments which follow . These
observations imply further that the reactivity observed in the test combinations
reported below is due to cross-reactivity between the products of two distinct
genes, H-2K and H-2D, and not to direct reactions between the products of
shared genes .
K-D Cross -Reactiuity .
￿
Hemagglutination and cytotoxic data demonstrating
extensive and reciprocal K-D cross-reactivity are summarized in Table IV (alb
recombinants), TableV (d/k recombinants), and Table VI (d/b recombinant) . A
plus (+) indicates a positive result in at least one of the two assays . In most cases,
TABLE IV
Antisera and Target Cells Tested for Cross-Reactivity, and Summary of Results (a/b
Recom binants)
DONAL B. MURPHY AND DONALD C . SHREFFLER
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*A positive reaction in either the microcytotoxic or hemagglutination assays is scored as a plus (+).
No reactivity in either assay system is scored as a minus (-) .
$Donor, recipient, and target strains all share the same alleles in this segment of chromosome . In
these combinations, one can immunize and test across a gap for this region . See text .
§ Absorption with afourth strain rulesout reactivity with determinants controlled by this segment of
chromosome . In these combinations, one can by this method effectivelyimmunize and test across a
gap for this region . See text.
11 Very weak but reproducible cytotoxic activity in this combination . See text .
Region
Region specifying
immu- antigen
Antiserum -No. nized which Target
Result* Gap
against might cell
cross-react
1310 anti-51? AS-37 Dd Kk 4R + I-13$
1310 anti-4R AS-49 Kk Dd HTI + I-B,I-C,S$
B10.A anti-2R AS-28 D° Kd B10.D2 (+)IL I-C,S$
BIO.A anti-2R AS-28 D° K° 51? - I-C,S$
B10.A anti-5R AS-25 K° D° 2R (+)II I-C,Sf
2R anti-B10.A AS-1 Dd Kn B10 + I-13,1-C,S§
4R anti-1310 AS-66 K° Dd B10.A + I-B,I-C,S§
5Ranti-1310 AS-10 D° Kk B10.A (+)~~ I-B,I-C,S§
5Ranti-B10.A AS-12 Kk D° B10 - I-B,I-C,S§382
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TABLE V
Antisera and Target Cells Tested for Cross-Reactiuity, and Summary of Results
(d/k Recombinants)
* A positive reaction in either the microcytotoxic or hemagglutination assays is scored as a plus (+) . No reactivity in
either assay system is scored as aminus (-) .
$ Donor, recipient, and target strains all share thesame alleles in this segment of chromosome . In this combination,
one can immunize and test across a gap for this region . See text .
§ Absorption with a fourth strain rules out reactivity with determinants controlled by this segment of chromosome .
In this combination, onecanby this method effectively immunize and test across a gap for this region . See text .
TABLE VI
Antisera and Target Cells Tested for Cross-Reactivity, and Summary of Results
(d/b Recombinants)
*A positive reaction in either the microcytotoxic or hemagglutination assays is scored as a plus (+) .
$Presence of certain regions in the F, recipient rules out reactivity with this segment of chromosome . In this
combination, one can immunize and test across a gap for this region . See text .
both cytotoxic andhemagglutinating activity were detected . However, with some
target cells, particularly those expressing K° determinants, cytotoxic reactions
but no red cell agglutination could be demonstrated . In addition to the eight
basic combinations that can be tested with four recombinant and two parental
types, secondary target strains which test for additional cross-reactions were also
tested and these results are included in the tables .
Antiserum No .
Region
immunized
against
Region
specifying
antigen
which
might
cross-react
Target
cell Result* Gap
CM anti-A.AL AS-73 Dd K° C3H.OL + S$
CM anti-OL AS-40 K° D" A.AL + S$
B10.D2anti-OH AS-77 DO Kk B10.A + I-C,S$
MOManti-B10.A AS-63 Kk DO C3H.OH + I-C,S$
MOManti-OH AS-77 DO K^ 5R + I-C,S$
B10.D2 anti-5R AS-123 K" DO C3H.OH + I-C,S$
OH anti-BI0.D2 AS-51 D" Kk CM + S§
OL anti-CM AS-54 Kk D° B10.D2 + S§
Bl0.Aanti-B10.BR AS-45 DO K" B10.D2 - I-C,S§
BIO.Aanti-B10.D2 AS-43 K" D° BIO.BR - I-C,S§
B10.A anti-B10.D2 AS-43 K" D^ 211 - I-C,S$
Region
Region specifying
Antiserum No . immunized antigen
which
Target
cell Result* Gap
against might
cross-react
(D2.GD xR103)F, anti-OH AS-131 DO Kk 411 + I-B,I-C,S$
D" K° B10 + I-B,I-C,S$
(D2.GD x R103)F, anti-1310.132 AS-132 Dd K" 411 + I-B,I-C,S$
D" K" B10 + I-B,I-C,S$
(D2.GD xR103)F, anti-1310 AS-134 K° DO OH + I-B,I-C,S$
K° D" Bl0.D2 + I-B,I-C,S$DONAL B . MURPHY AND DONALD C . SHREFFLER
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Wherever a cross-reaction was observed, a gap exists at least for theS region,
or, in the case of B10 anti-5R, a gap for I-B . In each case, one can infer that
antibody directed against the product of some gene to the left of S or I-B reacts
with an antigen controlled by a gene to the right ofS or I-B, or vice versa. Several
observations strongly suggest that the products of the H-2K and H-2D genes are
involved in this reactivity, and not the closely linked Ia or Tla genes, which also
control membrane alloantigens . First, no Ia determinants have been reported
which map to the right of S. Second, in most combinations tested, greater than
90% kill oflymph node targets is observed . Ia antisera routinely give amaximum
kill of 40-70% (8) . Third, Ia determinants are not present on red cells (8, 10) . Most
cases of cross-reactivity are detected by hemagglutination as well as by
cytotoxicity. Complications attributable to Tla are most unlikely, since Tla
antigens are not expressed on lymph node lymphocytes, which were the target
cells utilized in the cytotoxic assay (39) . Identification of the cross-reacting
specificities in these antisera as known H-2 public specificities lends further
credence to this interpretation . Absorption analyses have revealed cross-reacting
H-2.3, 5, 29, and 36 antibodies in these sera .I
Raw data from both the hemagglutination and cytotoxic assays are included in
Table VII (alb recombinants), Table VIII (d/k recombinants), and Table IX (djb
recombinants). Antiserum titers are reported as the reciprocal of the endpoint
dilution . Cytotoxic titers were determined by the dilution of antiserum giving
50% of themaximum specific lysis . Hemagglutination titers are based on the last
antiserum dilution giving a positive reaction . In the discussion below, reciprocal
antiserum combinations will be considered together to emphasize the generally
reciprocal nature of the presence or absence of K-D cross-reactivity .
B10 anti-5R (AS-37), B10 Anti-4R (AS-49). Both antisera gave positive
cytotoxic and hemagglutination cross-reactions with target cells from the
appropriate strain (Table IV, Table VII) . Preliminary results suggesting D-K
cross-reactivity in the B10 anti-5R combination were reported previously (30) .
No cross-reactive antibody was found in early bleedings in the B10 anti-4R
combination. Results with later bleedings demonstrated a positive reaction .
These antisera thus demonstrate reciprocal Kk-Dd cross-reactivity .
BIO.A Anti-2R (AS-28), B10.A Anti-5R (AS-25) . When tested with 5R target
cells, AS-28 exhibited no reactivity (Table IV, Table VII) . However, this
antiserum did give weak cytotoxicity with B10.D2 lymphocytes. The reciprocal
antiserum, AS-25, gave a weak cytotoxic reaction with 211 target cells. These
weak reactions probably reflect H-2 cross-reactivity, unless la determinants are
situated to the right ofS. These data thus imply weak one-way cross-reactions of
anti-D° with theKd product and of anti-K° with the D° product .
2R Anti-BlO.A (AS-1), 4R Anti-BIO (AS-66).
￿
Evidence forK-D cross-reactiv-
ity is apparent with both antisera (Table IV, Table VII) . As reported previously
(30), AS-1 gave a positive cytotoxic reaction with B10 . Since strain 411 did not
react with this antiserum, and failed to absorb activity for B10 targets, we can
infer that anti-Dd antibody reacts with K° antigen . One of the most surprising
a Murphy,D. B., andD . C. Shreffler . 1974 . Cross-reactivity betweenH-2K andH-2D products . II .
Identification of the cross-reacting specificities . Manuscript submitted for publication .384
TABLE VII
Dye Exclusion and Hemagglutination Data with alb Recombinant Combinations
* Reciprocal of antiserum dilution giving 50% of maximum specific lysis . Unless otherwise indicated, all antisera give a
maximum kill of 90% or greater, with a nonimmune serum control of 10% or less .
$ Reciprocal of last antiserum dilution giving agglutination.
§Dash (-) indicates not tested .
11 Maximum kill of approximately 50%, with nonimmune serum control of 10% or less .
4 Absorbed in vivo in strain 2R . See text .
TABLE VIII
Dye Exclusion and Hemagglutination Data with d/k Recombinant Combinations
CROSS-REACTIVITY BETWEEN H-2K AND H-2D PRODUCTS . I
* Reciprocal of antiserum dilution giving 50% of maximum specific lysis . Unless otherwise indicated, all antisera give a
maximum kill of 90% or greater, with nonimmune serum control of 10% or less .
$ Reciprocal of last antiserum dilution giving agglutination .
§Dash (-) indicates not tested .
11 Trace reaction .
Target
Titers by dye
C3H
AS-73
C3H
anti-
A.AL
exclusion*
0
AS-40
C3H
anti-
OL
0
AS-77
B10.D2
anti-
OH
-
AS-63
B10.D2
anti-
B10.A
-
AS-123
B10.D2
anti-5R
-
AS-51
OH anti-
B10.D2
220
AS-54
OL
anti-
C3H
1,900
AS-45
B10.A
anti-
B10.BR
-
AS-43
Bl0.A
anti-
B10.D2
-
BIO.BR -§ - - - - - - 720 0
B10.D2 - - 0 0 0 3,600 360 0 640
B10.A - - 500 15,000 - - - 0 0
A.AL 8,400 1,350 - - - - - - -
OH - - 150 180 120 0 0 - -
OL 280 9,000 - - - 0 0 - -
5R - - 110 - 155 - - - -
2R - - - - - - - - 0
Titers by hemagglutination$
C3H 0 0 - - - 40 640 - -
B10.BR - - - - - - - 0 0
B10.D2 - - 0 0 0 >2,560 160 0 80
BIO.A - - 160 >2,560 - - - 0 0
A.AL > 2,560 640 - - - - - - -
OH - - 160 320 320 0 0 - -
OL 160 Tril - - - 0 0 - -
5R - - 0 - 0 - - - -
2R - 0
AS-37
Target B10
anti-5R
AS-49
B10
anti-4R
AS-28
B10.A
anti-2R
AS-25
B10.A
anti-5R
AS-1
2R anti-
B10.A
AS-66
4R anti-
B10
AS-66
411 anti-
B10
AS-10
5R anti-
B10
AS-12
511 anti-
BlO.A
Titers by dye exclusion*
B10 0 0 - - 230 1,000 250 2,560 0
BIO.A -§ - 0 0 20,480 350 50 60Ij 8,500
2R - - 200 3011 0 13011 0 - -
4R 520 3,700 - - 0 0 - - -
5R 3,800 80 0 2,000 - - - 0 0
HTI - 65 - - - - - - -
B10.D2 - - 3011
Bl0.BR - 38011 5011
Titers by hemagglutination$
B10 0 0 - - 0 0 - 160 0
B10.A - - 0 - 1,280 160 20 0 640
2R - - 80 0 0 0 - - -
4R 320 >2,560 - - 0 0 - - -
5R >2,560 80 0 0 - - - 0 0
HTI - 320 - - - - - - -
B10.D2 - - 0 - - - - - -
B10.BR - 0TABLE IX
Dye Exclusion and Hemagglutination Data with d/b Re-
combinant Combinations
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* Reciprocal of antiserum dilution giving 50% of maximum specific lysis . Unless otherwise indicated,
all antisera give amaximum kill of90% or greater, with a nonimmune serum control of 10%or less .
$Reciprocal of last antiserum dilution giving agglutination .
§ Dash (-) indicates not tested .
11 Maximum kill of approximately 50%, with a nonimmune serum control of 10% or less .
results in this study was the cytotoxic reactivity of AS-66 with 211 lymphocytes
(Table VII) . Strains 211 and 411 are identical at theH-2Kand H-2D loci (Table 1) .
Therefore, this reaction should not be directed against the products of these
genes . The low level of cytotoxic kill (50%), and lack of hemagglutination with 211
red cells, may be suggestive of la reactivity . Moderate cytotoxic killing and no
hemagglutination was also obtained with cells from a second target strain,
1310.1311 (Table VII) . Absorption in strain KBR cleared this reactivity, suggesting
that the gene controlling the reactive determinant in 1310.1311 is positioned to the
left of H-2D . Failure of 211 tissues to absorb for 1310.1311 lymphocytes placed this
gene to the right of I-B . However, AS-66 also had both cytotoxic and
hemagglutinating activity for target cells from B10.A, the test strain for H-2
cross-reactivity . In vivo absorption in strain 211 did not clear this activity (Table
VII) . These data therefore also indicate a reciprocal K°-Dd cross-reactivity .
511 Anti-B10 (AS-10), 511 Anti-B10.A (AS-12) . A weak but reproducible
cytotoxic cross-reaction was observed with AS-10 (Table IV, Table VII) . In this
particular strain combination, la antibody potentially reactive with B10.A could
be present (anti-I-C°) . However, strain AQR failed to clear reactivity for B10.A,
thus suggestingH-2 reactivity . A negative reaction was observed in the reciprocal
direction (AS-12) . These data suggest a one-way cross-reaction of anti-D° with
Kk .
C3HAnti-A .AL (AS-73), C3H Anti-OL (AS-40) .
￿
Both antisera reacted with
appropriate targets cells (Tables V and VIII), implicating reciprocal Kd-D'
cross-reactivity .
BIOD2 Anti-OH (AS-77), B10.D2 Anti-BIO.A (AS-63) . Positive reactions
Target
AS-131
(D2.GD x
R103)F,
anti-OH
AS-132
n(D2.GD x
R103)F,
anti-B10.D2
AS-134
(D2.GD x
R103)F,
anti-1310
Titers by dyeexclusion*
(D2.GD x R103)F, 0 0 0
OH 45 -§ 4011
1310 120 115 4,300
411 130 2311 -
B10.D2 - 780 1911
Titers by hemagglutination$
(D2.GDx R103)F, 0 0 0
OH 80 - 320
1310 0 0 0
411 80 320 -
1310.D2 - 2,560 160386
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across a gap for the S region in both assay systems indicate reciprocal
cross-reactivity between Kk and Dk (Table V, Table VIII) .
MOMAnti-5R (AS-123) .
￿
This antiserum is included in Table V and Table
VIII to demonstrate K°-D" reactivity, and represents a second reciprocal partner
of AS-77 .
OH Anti-B10M (AS-51), OL Anti-C3H (AS-54) .
￿
The reciprocal cross-reac-
tivity with these combinations in both assay systems after absorption with OL
(AS-51) and OH (AS-54) to create a gap situation (Table V, Table VIII) is
comparable to that reported above with AS-37 and AS-49 (Table IV) . We thus
have a second, independent example ofreciprocal Kk-Dd reactivity .
B10.A Anti-B10M (AS-45), B10.A Anti-BIOM (AS-43) .
￿
When tested with
B10.D2 and B10.BR respectively, no reaction was observed, suggesting the
absence of cross-reactivity between Dk and Kd (Table V, Table VIII) .
(D2.GD x R103)F, Anti-OH (AS-131), (D2.GD x R103)F, Anti-B10M
(AS-132), (D2.GD x R103)F, Anti-B10 (AS-134) . Positive cytotoxic and/or
hemagglutination reactions with all target strains tested provide additional
examples of specific K-D cross-reactivity (Table VI, Table IX) . For example,
AS-132 gives a third, independent demonstration of cross-reactivity between
anti-Dd antibody and Kk antigen (compare with AS-37) (Table IV) and AS-51
(Table V) .
Unreactiuity ofKb Cells in Hemagglutination .
￿
Poor reactivity ofB10 red cells
in the hemagglutination assay was recognized in early studies of H-2 serology
(40) . In particular, anti-H-2 .5 antisera routinely fail to agglutinate K° targets,
regardless of strain background (41, 42). Data in this study further illustrate this
phenomenon . Antisera against Dd or Dk all gave positive cytotoxic reactions but
negative hemagglutination with Kb targets (AS-1, AS-77, AS-131, AS-132).
Despite the fact that Kb tissue was used as the donor in the preparation of AS-25,
AS-66, AS-123, and AS-134, no hemagglutinating activity was foundwith K° red
cells . These same antisera were cytotoxic for Kb target cells, however, and AS-66,
AS-123, and AS-134 did have hemagglutinating activity for other red cell types .
In contrast, when Db tissue was used as the donor, good hemagglutinating
activity was found with Db targets (AS-10, AS-28) .
Discussion
A summary of the K-D cross-reactivity detected this study is presented in
TableX. Two points are striking . (a) The observed cross-reactivity is extensive .
13 of 18 possible comparisons exhibited cross-reactivity betweenH-2K andH-2D .
In some cases, multiple combinations provide independent demonstrations of
cross-reactivity . For example, AS-37, AS-51, and AS-132 all show reactivity
between anti-Dd antibody and Kk antigen. On the basis of strong cytotoxic kill
and/or positive red cell agglutination, 10 of these combinations revealed
unequivocal reactivity between the products of the H-2K and H-2D genes . In
these particular combinations, the cross-reactive entities have been identified as
H-2 public specificities H-2.3, 5, 29, and 36 . 3 Three combinations exhibited
weak cytotoxic cross-reactivity . To date, no la-like activity has been mapped toDONAL B . MURPHY AND DONALD C . SHREFFLER
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TABLE X
Summary of Cross-Reactiuities* Detected between the Products
ofH-2K and H-2D Alleles
* (+) Denotes reciprocal cross-reaction, i.e . anti-D° antibody reacts with
K° product, and anti-K° with D° product . (-) Denotes reciprocal
absence of cross-reactivity . (f) Denotes weak one-way cytotoxic cross-
reaction of an anti-D serum with aKproduct, but not vice versa . (+)
Denotes weak one-way cytotoxic cross-reaction of an anti-K serumwith
a D product, but not vice versa .
the right of S. Consequently, the reactivity of these antisera is tentatively
attributed to H-2 antibody . (b) In most cases, the presence or absence of a
cross-reaction is reciprocal in nature . Since the exceptions are weak, reactivity in
the reciprocal direction could easily go undetected . Failure to find reactivity in
five combinations may simply reflect the presence of certain determinants in the
recipient . For example, AS-28, AS-43, and AS-45 were all produced in B10.A
recipients . Both Kk and Dn cross-react extensively (Table X) . Perhaps the
presence of these highly cross-reactive determinants in the recipient blocked
formation of potential cross-reactive antibody . As additional recombinants
involving other haplotypes become available, cross-reactivity may also be found
in these presently unreactive combinations .
Products of alternative alleles at the same locus (H-2K or H-2D) also, of
course, share cross-reactive public specificities (2, 17) . Dual comparisons
between the different H-2K alleles included in this study (K°, Kd, Kk) reveal that
two out of three of these pairs share a common specificity . A similar result is
found for comparisons between the different H-2D alleles studied (D°, Dd, D'p)
These estimates approximate that found in this report for cross-reactivity
between the products of the H-2K and H-2D loci . If this cross-reactivity reflects
structural homology, it would suggest that the similarity between the products of
different alleles at the same locus is no greater than that between products of the
two different loci . Biochemical studiesseem to be consistent with this interpreta-
tion . Nathenson and Cullen (29) have reported that preliminary peptide maps
reveal almost as much similarity between the products of the H-2K and H-2D
genes as between the products of different alleles at H-2D . These data are
precisely what one would expect if the H-2K and H-2D genes arose through
duplication of a common ancestral gene and were both concomitantly modified
by mutation . Complete amino acid sequencing of these gene products may be
required to resolve this problem .
The cytotoxic reaction of 411 anti-B10 (AS-66, Table VII) with 2R target cells
was unexpected . The 4R and 2R strains share the same H-2K and H-2D alleles.
Reactivity therefore must be with determinants controlled by other genes which
H-2D allele
H-2K allele
D° D° D"
K° t + +
K° t + -
K" 3 + +388
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map between these two loci . The absence of red cell agglutination and the
maximum kill of 50% with 211 lymph node targets would be consistent with the
behavior of an la reaction . Since no la determinants have been localized to the
right of S, these data may reflect a cross-reaction of antibody directed against
products of the I-A region with determinants controlled by I-B or I-C. Reactivity
with the I-C region is implicated from results obtained with a second target
strain, B10.BR . Alternatively, reactivity in this combination might reflect a
cross-reaction between H-2 antibody (anti-H-2K) and an la determinant (I-C
antigen) . This alternative appears less likely, since the molecules encoded by
these two systems are biochemically distinct . Regardless of whether anti-la or
anti-H-2 antibody is involved, this reactivity suggests serological cross-reactivity
with the product of a gene other than H-2K or H-2D .
Attempts to demonstrateK-D cross-reactivity by skin graft rejection have also
been successful .4 Prior sensitization of a recipient with tissue-bearing H-2K
determinants results in the accelerated rejection of a graft expressing cross-reac-
tive H-2D determinants, and vice versa . Using an experimental design compara-
ble to that employed here, Nabholz et al . (43) have demonstrated a similar K-D
cross-reaction in vitro in the cell-mediated lympholysis assay . Prior sensitization
of lymphocytes with H-2K tissue can generate T-"killer" cells capable of
destroying targets expressing cross-reactive H-2D determinants . This supports
the idea that the accelerated graft rejection observed in vivo may be due to
cross-sensitization at the cell-mediated level of immunity .
In conclusion, extensive and reciprocal serological cross-reactivity has been
demonstrated between the products of the H-2K and H-2D loci . Controls
designed to test for possible shared determinants in the combinations examined
make alternative interpretations most unlikely . These data validate the key
assumption underlying the current two-region interpretation for control of the
classical H-2 specifications . The observation of apparently comparable cross-
reactivity between la determinants serves as a warning that the pitfalls
encountered in early H-2 serology may also appear in the analysis of this new
antigenic system .
Summary
Serological cross-reactivity between the products of the H-2K and H-2D genes
has been demonstrated by a design in which antibody was produced against
determinants controlled by one locus (e .g . H-2K"), and then tested against the
product of the opposite locus (e.g . H-2Dd) . A total of 13 out of 18 such test
combinations exhibited H-2K-H-2D cross-reactivity . The presence or absence of
cross-reactivity was reciprocal in most cases (i.e . antibody directed against the
H-2K" gene product reacted with H-21)d determinants, and antibody directed
against the H-2Dd gene product reacted with H-2Kk determinants) . An la-like
reaction was detected with one antiserum which impliedpossible cross-reactivity
between the products of two discrete la genes.
Murphy,D. B., andD. C. Sbreffler . 1974 . Cross-reactivity betweenH-2K andH-2D products . 111 .
Effect of H-2K-H-2D cross-sensitization on skin graft survival . Manuscript submitted for publica-
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